Omid Hamid

24PUBLICATIONS
211CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)NanomedicineMedical devicesMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Aug 27, 2026
A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.

|Aug 18, 2026
Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.

|Feb 16, 2026
LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial.

O Hamid, V Ekström-Rydén, I Mehmi

|Jul 25, 2025
First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.

Omid Hamid, Dana B Cardin, F Stephen Hodi

|Jul 09, 2025
First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.

John D Powderly, Martin E Gutierrez, Ani S Balmanoukian

|Jul 09, 2025
First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors.

Martin E Gutierrez, Shou-Ching Tang, John D Powderly

Pageof 4

Frequent Collaborators

4 joint publications

Inderjit Mehmi

3 joint publications

James M G Larkin

3 joint publications

Sajeve S Thomas

3 joint publications

Jeffrey Chou